MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - pharmaceuticals
- ASTRAZENECA PHARMA - PFIZER
ASTRAZENECA PHARMA vs PFIZER - Comparison Results
ASTRAZENECA PHARMA Change
AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
PFIZER 
Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More
Current Valuations
| ASTRAZENECA PHARMA | PFIZER | ASTRAZENECA PHARMA/ PFIZER |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 80.3 | 35.7 | 225.2% | View Chart |
| P/BV | x | 24.3 | 6.1 | 398.6% | View Chart |
| Dividend Yield | % | 0.0 | 0.6 | - |
Financials
 ASTRAZENECA PHARMA  PFIZER |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| ASTRAZENECA PHARMA Mar-18 |
PFIZER Mar-19 |
ASTRAZENECA PHARMA/ PFIZER |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,278 | 3,840 | 33.3% | |
| Low | Rs | 883 | 2,080 | 42.4% | |
| Sales per share (Unadj.) | Rs | 228.4 | 455.0 | 50.2% | |
| Earnings per share (Unadj.) | Rs | 10.4 | 93.8 | 11.1% | |
| Cash flow per share (Unadj.) | Rs | 16.3 | 109.4 | 14.9% | |
| Dividends per share (Unadj.) | Rs | 0 | 22.50 | 0.0% | |
| Dividend yield (eoy) | % | 0 | 0.8 | 0.0% | |
| Book value per share (Unadj.) | Rs | 98.8 | 658.2 | 15.0% | |
| Shares outstanding (eoy) | m | 25.00 | 45.75 | 54.6% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 4.7 | 6.5 | 72.7% | |
| Avg P/E ratio | x | 104.2 | 31.6 | 330.2% | |
| P/CF ratio (eoy) | x | 66.4 | 27.1 | 245.5% | |
| Price / Book Value ratio | x | 10.9 | 4.5 | 243.2% | |
| Dividend payout | % | 0 | 24.0 | 0.0% | |
| Avg Mkt Cap | Rs m | 27,008 | 135,420 | 19.9% | |
| No. of employees | `000 | 1.4 | 2.6 | 51.5% | |
| Total wages/salary | Rs m | 1,535 | 3,238 | 47.4% | |
| Avg. sales/employee | Rs Th | 4,210.9 | 7,911.4 | 53.2% | |
| Avg. wages/employee | Rs Th | 1,132.2 | 1,230.9 | 92.0% | |
| Avg. net profit/employee | Rs Th | 191.1 | 1,630.7 | 11.7% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 5,710 | 20,815 | 27.4% | |
| Other income | Rs m | 123 | 1,674 | 7.3% | |
| Total revenues | Rs m | 5,833 | 22,489 | 25.9% | |
| Gross profit | Rs m | 463 | 5,712 | 8.1% | |
| Depreciation | Rs m | 147 | 714 | 20.6% | |
| Interest | Rs m | 0 | 73 | 0.0% | |
| Profit before tax | Rs m | 438 | 6,599 | 6.6% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 179 | 2,309 | 7.7% | |
| Profit after tax | Rs m | 259 | 4,291 | 6.0% | |
| Gross profit margin | % | 8.1 | 27.4 | 29.5% | |
| Effective tax rate | % | 40.8 | 35.0 | 116.8% | |
| Net profit margin | % | 4.5 | 20.6 | 22.0% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 3,209 | 27,167 | 11.8% | |
| Current liabilities | Rs m | 2,070 | 8,917 | 23.2% | |
| Net working cap to sales | % | 20.0 | 87.7 | 22.8% | |
| Current ratio | x | 1.6 | 3.0 | 50.9% | |
| Inventory Days | Days | 72 | 68 | 106.7% | |
| Debtors Days | Days | 35 | 30 | 116.0% | |
| Net fixed assets | Rs m | 790 | 8,862 | 8.9% | |
| Share capital | Rs m | 50 | 458 | 10.9% | |
| "Free" reserves | Rs m | 2,419 | 29,656 | 8.2% | |
| Net worth | Rs m | 2,469 | 30,113 | 8.2% | |
| Long term debt | Rs m | 0 | 25 | 0.0% | |
| Total assets | Rs m | 4,605 | 39,400 | 11.7% | |
| Interest coverage | x | NM | 91.5 | - | |
| Debt to equity ratio | x | 0 | 0 | 0.0% | |
| Sales to assets ratio | x | 1.2 | 0.5 | 234.7% | |
| Return on assets | % | 5.6 | 11.1 | 50.8% | |
| Return on equity | % | 10.5 | 14.2 | 73.6% | |
| Return on capital | % | 17.7 | 22.1 | 80.1% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 300 | 428 | 69.9% | |
| Fx outflow | Rs m | 2,015 | 786 | 256.2% | |
| Net fx | Rs m | -1,715 | -358 | 479.0% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 88 | 978 | 9.0% | |
| From Investments | Rs m | -94 | 351 | -26.7% | |
| From Financial Activity | Rs m | NA | -1,099 | 0.0% | |
| Net Cashflow | Rs m | -6 | 231 | -2.5% | |
Share Holding
| Indian Promoters | % | 0.0 | 0.0 | - | |
| Foreign collaborators | % | 75.0 | 63.9 | 117.4% | |
| Indian inst/Mut Fund | % | 0.3 | 7.5 | 4.0% | |
| FIIs | % | 15.7 | 4.9 | 320.4% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 9.1 | 23.7 | 38.4% | |
| Shareholders | 12,856 | 85,207 | 15.1% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASTRAZENECA PHARMA With: DISHMAN PHARMA ELDER PHARMA ALEMBIC LTD DR. DATSONS LABS CADILA HEALTHCARE
Compare ASTRAZENECA PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Today's Market
Sensex Ends 674 Points Lower; Banking and Finance Stocks Witness Selling(Closing)
Indian share markets witnessed selling pressure throughout the day and ended lower. Investors were worried about the economic impact and uncertainty over the coronavirus pandemic.
Related Views on News
PFIZER Announces Quarterly Results (3QFY20); Net Profit Up 5.4% (Quarterly Result Update)
Feb 19, 2020 | Updated on Feb 19, 2020For the quarter ended December 2019, PFIZER has posted a net profit of Rs 1 bn (up 5.4% YoY). Sales on the other hand came in at Rs 5 bn (up 4.7% YoY). Read on for a complete analysis of PFIZER's quarterly results.
PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)
Oct 29, 2019 | Updated on Oct 29, 2019For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.
PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)
Aug 13, 2019 | Updated on Aug 13, 2019For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)
Aug 8, 2019 | Updated on Aug 8, 2019For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)
May 29, 2019 | Updated on May 29, 2019For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.
More Views on NewsMost Popular
Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)
Mar 30, 2020This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...
The Biggest Trading Opportunity of 2020 is Here...
Mar 26, 2020India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!
A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)
Mar 25, 2020I see a big opportunity to make fast profits on the horizon.
Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock(Profit Hunter)
Mar 24, 2020Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.
One Stock that is All Charged Up for the Post Coronavirus Rebound(The 5 Minute Wrapup)
Apr 1, 2020A stock with strong moat is currently trading near 5-year lows.
MoreOUR TOP 5 IDEAS
- How to Trade the Coronavirus Crash - Download this FREE Report Now
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- A Guide to some of the Most Lucrative Stocks in the Market. Download For Free!
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- Find Out Our Top 7 Bluechips for 2020 Virtually FREE. Click Here Now!
ASTRAZENECA PHARMA SHARE PRICE
Apr 3, 2020 (Close)
TRACK ASTRAZENECA PHARMA
- Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ASTRAZENECA PHARMA
ASTRAZENECA PHARMA 5-YR ANALYSIS
COMPARE ASTRAZENECA PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.